# Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

> **NCT07277322** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Dan Feng** · enrollment: 24 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07277322
- **Lead sponsor:** Dan Feng
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07277322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07277322, "Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07277322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*